Literature DB >> 6195136

The importance of cross-reactions between species: mouse allo-anti-Ia monoclonal antibodies as a powerful tool to define human Ia subsets.

R S Accolla, D Birnbaum, M Pierres.   

Abstract

Three mouse allo-anti-Ia monoclonal antibodies recognizing epitopes specific for either I-E gene products (H81.98.21 and H40.315.7 Mabs) or shared between I-E and I-A gene products (H82.246.3 Mab) were used to analyze the human Ia molecules against which they cross-react. The results indicated that in the Ia pool of the human B cell line Raji the three Mabs were able to recognize at least three distinct subsets differing each other both in their alpha as well as in their beta subunits. The comparison with the previously defined human Ia subsets NG1, NGe, and DC1 suggested the following similarities: H81.98.21 specific Ia molecules similar to NG1; H82.246.3 specific Ia molecules similar to NG2, and including probably NG1; H40.315.7 specific molecules similar to DC1 in their alpha subunits and probably heterogeneous in their beta subunits with characteristics of the DC1, NG1, and NG2 subunits altogether. The heterogeneity of the human Ia molecules and the possible similarities with the mouse Ia system were discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195136     DOI: 10.1016/0198-8859(83)90084-8

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  2 in total

1.  Differentiation of canine bone marrow cells with hemopoietic characteristics from an adherent stromal cell precursor.

Authors:  R Huss; D S Hong; P A McSweeney; C A Hoy; H J Deeg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

2.  Analysis of the structural heterogeneity and polymorphism of human Ia antigens. Four distinct subsets of molecules are coexpressed in the Ia pool of both DR1,1 homozygous and DR3,W6 heterozygous B cell lines.

Authors:  R S Accolla
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.